-
Bojian was sued by insurance company Humana for illegally promoting drug sales through charitable donations
Time of Update: 2021-10-22
Biogen is also one of the pharmaceutical companies that previously signed a settlement agreement with the US government, but now the medical insurance giant Humana is filing a new lawsuit against the company's illegal charitable donations .
-
Hengrui Medicine's 1.3 billion innovative drug Punaburin will be another wealth code?
Time of Update: 2021-10-22
Figure 2 The inhibitory activity of punabulin on tumor cell lines and drug-resistant tumor cell linesIn 2011, Professor Hayashi summarized the structure-activity relationship of punabrine modified by phenylahistin (see Figure 3): 1.
-
Drug Administration: Kangye Medical Devices and Zhongyi Technology are recalling a batch of medical devices
Time of Update: 2021-10-22
On September 27, the State Food and Drug Administration issued an announcement to notify Kangye Medical Devices and Zhongyi Technology of the voluntary recall of some of its products in violation of regulations .
-
The internationalization of Chinese medicine has entered the "fast lane", and these problems need to be resolved urgently
Time of Update: 2021-10-22
The industry believes that these products have accelerated and successfully launched in overseas markets, marking a key breakthrough in the internationalization of Chinese medicine, and Chinese medicine companies have entered the international market .
-
Two injections of Sansheng Guojian were approved for clinical use
Time of Update: 2021-10-22
On October 8, Sansheng Guojian issued an announcement stating that the company has recently received 4 "Drug Clinical Trial Approval Notices" approved and issued by the State Food and Drug Administrat
-
Ruike Biotechnology and Ruiji Biotechnology reached an mRNA vaccine cooperation agreement
Time of Update: 2021-10-22
The joint venture company will use mRNA technology and new adjuvant technology to develop a new generation of new crown vaccines, and plans to gradually expand to other major infectious disease vaccines and tumor therapeutic vaccines .
-
National Food and Drug Administration: Conversion of Aloe Pearl Capsules from Prescription Drugs to Over-the-Counter Drugs
Time of Update: 2021-10-22
Variety of over-the-counter drug instructions templateAloe Pearl Capsule InstructionsPlease read the instructions carefully and use according to the instructions or purchase and use under the guidance of a pharmacist[Drug Name]Generic name: aloe pearl capsulesChinese Pinyin:[Ingredients][Properties][Functions and Indications] Clearing heat and leading to stagnation, promoting qi and defecation .
-
Amgen's lipid-lowering drug Repatha receives FDA approval to treat children with HeFH cholesterol disease
Time of Update: 2021-10-22
CompilationFan DongdongA few days ago, the FDA announced that it would approve the use of Amgen’s PCSK9 inhibitor Repatha as an additional treatment for dietary adjustments and statins for the treatment of pediatric patients 10 years of age and older with heterozygous familial hypercholesterolemia (HeFH).
-
Andorra's third-generation oral breast cancer Class 1 new drug was approved for clinical use in the U.S.
Time of Update: 2021-10-22
On October 1, the third-generation oral breast cancer class 1 new drug AND019 independently developed by Andorra Pharmaceuticals obtained clinical approval from the US FDA .
-
A new target for tumor immunity!
Time of Update: 2021-10-22
Preclinical studies have shown that SIM0235 has high binding specificity, can effectively block the activation of NF-κB signaling pathway induced by the combination of tumor necrosis factor α (TNFα) and TNFR2, effectively inhibit the proliferation and function of Treg cells, and regulate the immune microenvironment .
-
Centralized procurement to promote insulin and Chinese patent medicines to promote drug bidding in one place and publish new "retaliatory" regulations
Time of Update: 2021-10-22
Looking back at the first round of the first-round list of 20 key monitored drugs issued by the National Health and Medical Commission, they did not include proprietary Chinese medicines .
On September 25th, Hubei issued an announcement on the centralized procurement of the Inter-Provincial Volume Procurement Alliance of Chinese Patent Medicines .
-
Summary and outlook of the pharmaceutical equipment industry in the first three quarters of 2021
Time of Update: 2021-10-22
The industry believes that or indirectly brings development opportunities to the upstream pharmaceutical equipment industry; another example is Chinese medicine formula granules.
Favorable policy advancement, entering the fourth quarter, the pharmaceutical equipment industry is expected to continue its growth trend .
-
In the third quarter, cell therapy and gene editing were frequently favored by capital
Time of Update: 2021-10-22
For example, on July 30 this year, the newly established Xingyiang Biotech announced the completion of a US$40 million angel round of financing led by Eli Lilly Asia Fund.
-
Total failure!
Time of Update: 2021-10-22
Even so, the failure of the first mid-term ulcerative colitis study of deucravacitinib was undoubtedly a setback for Bristol-Myers Squibb's decision to uninstall the Otezla drug candidate .
-
Hengrui wins the first review with 2 billion anesthetics
Time of Update: 2021-10-22
Author: Bai YuA few days ago, Hengrui Pharmaceuticals issued an announcement stating that the company has been approved for inhalation sevoflurane for imitation of the 4 types of applications and is deemed to have been reviewed.
-
A large number of new drugs have been approved, highlighting the continuous improvement of the innovation capabilities of local pharmaceutical companies
Time of Update: 2021-10-22
According to statistics, under the background that the enthusiasm of various pharmaceutical companies for the research and development of innovative drugs has not diminished, as of now, the number of domestically produced Class 1 new drugs approved in the first half of 2021 has exceeded the entire year of 2020, a record high .
-
The domestic pharmaceutical machinery industry is ushering in a new period of development opportunities, and two major problems need to be resolved urgently
Time of Update: 2021-10-22
In addition, under the "three-child concept", the demand for children's drugs may also grow further, and the production capacity of related pharmaceutical companies is expected to usher in a new round of expansion and upgrade, and this impact may also indirectly affect the upstream pharmaceutical equipment industry.
-
Many places began to implement the fifth batch of national sourcing of medicines, and a new competition pattern in the pharmaceutical market is approaching
Time of Update: 2021-10-22
It is reported that the fifth batch of national procurement of medicines has a total of 61 products selected, with an average decrease of 56%; the varieties involve common diseases such as hypertension, diabetes, coronary heart disease, digestive tract diseases, and drugs for chronic diseases, as well as drugs for major diseases such as lung cancer and pancreatic cancer.
-
With the continuous expansion of the market size of Chinese herbal medicine decoction pieces, ensuring high-quality development has become a top priority
Time of Update: 2021-10-22
. Industry analysis believes that, in fact, in recent years, market regulatory authorities in various regions have been constantly "strikes out", strengthened special rectification of traditional Chinese medicine decoction pieces, actively promoted standardized production, strengthened supervision of pesticide residues, and regulated the operation and use behavior of traditional Chinese medicine decoction pieces.
-
Weijian Pharmaceuticals and China Rare Disease Alliance strategically cooperate to help the construction of a healthy ecology for rare diseases
Time of Update: 2021-10-22
Boao, Hainan, October 8, 2021/PRNewswire/ - September 30, 2021 (Hainan·Boao), Hong Kong Weijian Pharmaceutical Group ("Vaijian Pharmaceutical") and China Rare Disease Alliance formally signed a five-y
